ArticleJournal of global health2026
Time-varying characteristics of remdesivir-treated patients hospitalised due to COVID-19: an electronic health record study.
Article in Journal of global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Remdesivir is a pivotal antiviral treatment introduced during the COVID-19 pandemic, and its use has changed over time. This provided an opportunity to study how drug usage evolves over the course of a pandemic. Our study aimed to examine key physiological parameters of patients hospitalised due to COVID-19, how the characteristics of patients evolved, and explore if potential differences were similar across time for patients treated with remdesivir and those not treated. Methods: This study sourced electronic health care records from the Capital Region of Denmark. Patients aged ≥12 years hospitalised for the first time due to COVID-19 between 4 June 2020 and 1 December 2021 were included. Three time periods based on World Health Organization (WHO) treatment recommendations were used to describe temporal changes in the propensity score for remdesivir treatment as well as in individual patient characteristics. Results: In total, 6960 patients were included. The key differences between remdesivir-treated (n = 2557) and non-treated (n = 4403) were an elevated c-reactive protein (CRP) (median of 79 vs. 35 mg/L) and increased use of glucocorticoids (41.5% vs. 10%) and antithrombotics (48.5% vs. 18.5%). When describing the temporal changes in the propensity score, there was an overall significant interaction between the time period and exposure group. From the first to the middle period for the non-treated there was a significant increase in the mean propensity score of 0.04 (95% confidence interval (CI) = 0.02-0.06). The patient characteristics that had the largest temporal variations for remdesivir-treated patients were age, alanine transaminase, mechanical ventilation, interleukin-6 inhibitors, glucocorticoids, and antithrombotics. Conclusions: In conclusion, we found that remdesivir-treated and non-treated patients exhibited distinct sociodemographic and physiological characteristics. Also, the use of other COVID-19 treatments evolved differently between remdesivir-treated and not treated over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.